AlzGene - Gene overview of all published AD-association studies for SERPINA3
Back Search Methods Disclaimer Credits
 Gene: SERPINA3  (ACT; AACT; GIG24; GIG25)  Entrez Gene    View on PDGene   View on SZGene
 Protein: serpin peptidase inhibitor, clade A, member 3  (antichymotrypsin; alpha-1-antichymotrypsin)  ProteinLink
 Chromosome: 14   (View: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  X  Y  MT)
 Status: Updated 18 April 2011
Meta-Analysis
1. Case-Control Studies (by ethnic group)
      AD Cases Normal Controls    
Study Population Source # Polys # Subjects
(% women)
DX Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result Comment
 Caucasian
Bass, 1998
USA CL  1  (detail)  284
(57%)
C67.1 + 8.5
(40-85)
72.1 + 7.9
(42-93)
171
(56%)
69.3 + 7.9
(37-86)
Negative
Belbin, 2007
UK CL  5  (detail)  668
(44%)
M69.8 + 12
(-)
-419
(51%)
68 + 15.7
(-)
Negative
Christie, 1996
Overlaps with
Lamb, 1998
CL  1  (detail)  109
(-)
N-77.8 + 9.3
(46-94)
101
(-)
76 + 8.9
(59-104)
n.a. 
Clarimon, 2003
Spain CL  1  (detail)  112
(73%)
C-76.7 + 5.4
(-)
89
(53%)
74.8 + 5.2
(-)
Negative
DeKosky, 1996
Overlaps with
Kamboh, 1995
CL,PO  1  (detail)  -U----n.a.
Didierjean, 1997
France CL  1  (detail)  314
(70%)
C66.7 + 11.8
(-)
-173
(53%)
61.7 + 10.1
(-)
Negative
Durany, 1998
Germany CL  2  (detail)  56
(54%)
N-72.4 + 9.2
(55-95)
70
(47%)
72.2 + 8.8
(55-95)
Negative 
Durany, 1999
Germany CL  1  (detail)  63
(67%)
C-74.7 + 9.3
(46-90)
65
(60%)
71.7 + 8.5
(48-92)
Negative 
Durany, 2000
Overlaps with
Durany, 1999
   1  (detail)  -U----n.a.
Egensperger, 1997
Germany CL  1  (detail)  28
(75%)
N-78.1
(-)
100
(54%)
74.3
(-)
Negative
Emahazion, 2001
Scotland CL  1  (detail)  121
(-)
C--152
(-)
-Negative
Ezquerra, 1998
Spain CL  1  (detail)  136
(-)
U-64.4 + 9.6
(-)
92
(-)
67 + 11.8
(-)
Positive
Giedraitis, 2009
Sweden (ULSAM) CL  2  (detail)  86
(0%)
C80.2
(72-85)
-404
(0%)
81.8
(80-84)
Negative
Helisalmi, 1997
Finland CL  1  (detail)  218
(67%)
C-78 + 9
(-)
101
(84%)
71 + 10
(-)
Negative
Itabashi, 1998
USA CL  1  (detail)  86
(-)
N-77.9
(59-92)
29
(-)
64.2
(18-92)
Negative
Kamboh, 1995
USA CL  1  (detail)  225
(64%)
M-74.6
(22-101)
315
(69%)
53
(24-92)
Positive
Lamb, 1998
UK CL  1  (detail)  108
(-)
N-77.8 + 9.3
(46-94)
101
(-)
76 + 8.9
(59-104)
Trend
Li, 2008
Canada CL  1  (detail)  753
(58%)
C71.9 + 8.5
(-)
77.8 + 8.6
(-)
736
(64%)
73.4 + 7.9
(-)
Negative
Licastro, 1999
Italy CL  1  (detail)  260
(61%)
C-73.8 + 1
(-)
186
(33%)
60 + 1
(50-92)
Positive
Licastro, 2000
Overlaps with
Licastro, 1999
   1  (detail)  ------n.a.
Licastro, 2005
Italy CL  1  (detail)  422
(-)
C-74 + 8
(-)
433
(-)
67 + 12
(-)
Positive
Licastro, 2005
UK CL  1  (detail)  19
(-)
N-59 + 7.1
(-)
28
(-)
62 + 2
(-)
Positive
Licastro, 2006
Overlaps with
Licastro, 1999 & 2005
CL  2  (detail)  260
(-)
C--190
(-)
-n.a.
McIlroy, 2000
Ireland CL  1  (detail)  108
(67%)
C74.4
(-)
78 + 6.1
(65-90)
108
(67%)
78.3 + 5.9
(65-90)
Positive
Morgan, 1997
Unknown CL  2  (detail)  195
(-)
N-80.8 + 9.8
(55-101)
126
(-)
72.8 + 9
(58-91)
Positive
Muller, 1996
Germany CL  1  (detail)  147
(-)
U--74
(-)
-Negative
Nacmias, 1996
Italy CL  1  (detail)  100
(-)
C57.4 + 4.5
(-)
-103
(-)
74.5 + 25.1
(19-106)
Negative
Nacmias, 1998
Overlaps with
Nacmias, 1998
   1  (detail)  -U----Negative
Papassotiropoulos, 2003
Europe (mixed) CL  1  (detail)  153
(-)
C--181
(-)
-Negative
Reiman, 2007
USA, Netherlands CL  1  (detail)  861
(-)
M-74.9 + 6.6
(-)
550
(-)
77.4 + 7.3
(-)
Negative
Retz, 2001
Germany CL  1  (detail)  63
(68%)
C66.6 + 11.9
(-)
73.7 + 9.3
(-)
162
(62%)
70.6 + 8.2
(-)
Negative
Rodriguez, 2000
Israel CL  1  (detail)  121
(64%)
C-73.2
(-)
125
(68%)
79.6
(-)
Negative
Scacchi, 1999
Italy CO  1  (detail)  85
(76%)
C-86.1 + 3.8
(81-95)
156
(58%)
83.8 + 3.2
(74-99)
Trend
Scacchi, 2001
Overlaps with
Scacchi, 1999
   1  (detail)  -U----n.a.
Talbot, 1996
Unknown    1  (detail)  202
(60%)
U69.9 + 8.6
(44-92)
76.6 + 9.6
(-)
133
(59%)
75.5 + 12.2
(-)
Negative
Thome, 1995
Germany    1  (detail)  17
(47%)
C--58
(-)
-Positive
Wang, 1998
Overlaps with
Kamboh, 1995
   1  (detail)  -U----n.a.
Wang, 2002 (I)
Overlaps with
Kamboh, 1995
CL  7  (detail)  567
(68%)
M71.2 + 6.1
(-)
77.4 + 6.4
(-)
319
(68%)
73.9 + 5
(-)
n.a.
Wang, 2002 (II)
Overlaps with
Kamboh, 1995
   7  (detail)  -U----n.a.
 African Descent
Perry, 2001
USA CL  1  (detail)  111
(78%)
M70.8 + 7.8
(-)
71.3 + 7.7
(-)
78
(76%)
75.2 + 7.6
(-)
Negative
 Asian
Hu, 2000
Taiwan CL  1  (detail)  82
(-)
C-78.2
(62-96)
110
(-)
79.2
(67-87)
Negative
Ki, 2001
Korea CL  1  (detail)  89
(78%)
C73.1 + 5.8
(-)
-50
(58%)
73.2 + 7.8
(-)
Negative
Kim, 2000
Korea CL  1  (detail)  110
(-)
C-70 + 7.8
(-)
209
(-)
68.2 + 4.6
(-)
Negative
Kim, 2000
Overlaps with
Kim, 2000
   1  (detail)  -U----n.a.
Meng, 2000
China CL  2  (detail)  33
(48%)
C68.4 + 8.9
(49-87)
73 + 9.8
(51-96)
246
(46%)
75.8 + 7.9
(60-93)
Positive
Muramatsu, 1996
Japan CL  2  (detail)  101
(68%)
C-76 + 8.9
(-)
104
(47%)
73 + 9.2
(-)
Positive
Sodeyama, 1999
Overlaps with
Yamada, 2002
   1  (detail)  -U----n.a.
Tang, 2000
China CL  1  (detail)  125
(49%)
C70.6 + 8.6
(50-89)
-140
(57%)
52 + 18.6
(30-81)
Negative
Wang, 1999
China CL  1  (detail)  157
(43%)
C-72.8 + 8.7
(-)
114
(39%)
72.9 + 3.5
(-)
Negative
Yamada, 1998
Overlaps with
Yamada, 2002
   1  (detail)  -U----n.a.
Yamada, 2002
Japan CL  1  (detail)  82
(-)
N-86.1 + 7.9
(62-104)
119
(-)
85.7 + 8
(65-103)
Negative
Yamanaka, 1998
Japan    1  (detail)  65
(68%)
C51
(-)
-200
(-)
-Negative
Yoshiiwa, 1997
Japan CL  1  (detail)  139
(69%)
C74.2 + 7.1
(65-94)
79 + 6.8
(66-98)
250
(64%)
79.8 + 7.9
(65-101)
Positive
Yoshizawa, 1997
Japan CL  1  (detail)  82
(78%)
M-74.1 + 10
(47-95)
277
(-)
49.3 + 8.6
(29-75)
Negative
Yu, 2010
China CL  4  (detail)  244
(57%)
C70 + 9.5
(-)
74.9 + 8.3
(-)
205
(56%)
69.6 + 10.6
(-)
Negative
 Other/Mixed
Fallin, 1997
USA & UK CL,PO  1  (detail)  93
(-)
C72.9 + 7.4
(-)
-112
(-)
73 + 7.1
(-)
Negative
Haines, 1996 (I)
USA CL  1  (detail)  576
(63%)
C69.1 + 8.6
(-)
-535
(-)
-Negative
Haines, 1996 (II)
Same as Haines, 1996 (I)    1  (detail)  -U----n.a.
Murphy, 1997
USA CL  1  (detail)  160
(44%)
M65.8 + 8
(42-86)
74.4 + 8.1
(47-96)
142
(60%)
60 + 17.1
(20-87)
Negative
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine AD diagnosis ->  "C" (clinical AD diagnosis), "N" (neuropathological AD diagnosis), "M" (mixed, i.e. AD sample contains both clinical and neuropathological cases), "U" (unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between); results obtained in duplicate or largely overlapping samples are listed as "n.a.".
(-) :  Either no data provided or in case of overlap, data included in original study.
AlzGene Recent Updates
AlzGene Top Results
AlzGene Stats
Studies: 1395
Genes: 695
Polymorphisms: 2973
Meta-analyses: 320
Cure Alzheimer's Fund
Proud supporter of the AlzGene database.
Michael J. Fox Foundation
The PDGene database is supported by a grant from The Michael J. Fox Foundation in partnership with the Alzheimer Research Forum.

NCRAD

The National Cell Repository for Alzheimer Disease seeks to recruit 1,000 families with two or more living brothers or sisters who have been diagnosed with late onset Alzheimer’s disease.
ALSGene
AlzGene
MSGene
PDGene
SZGene
An up-to-date collection of all published genetic association studies.